Nasser Khan
About
Nasser Khan is a scholar working on Rheumatology, Hematology and Genetics.
According to data from OpenAlex, Nasser Khan has authored 27 papers receiving a total of 995 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Rheumatology, 15 papers in Hematology and 6 papers in Genetics. Recurrent topics in Nasser Khan's work include Rheumatoid Arthritis Research and Therapies (22 papers), Autoimmune and Inflammatory Disorders Research (15 papers) and Systemic Lupus Erythematosus Research (7 papers). Nasser Khan is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (22 papers), Autoimmune and Inflammatory Disorders Research (15 papers) and Systemic Lupus Erythematosus Research (7 papers). Nasser Khan collaborates with scholars based in United States, Germany and Japan. Nasser Khan's co-authors include Aileen L. Pangan, Heidi S. Camp, Jeffrey Enejosa, Gerd R Burmester, Ahmed A. Othman, Li Wang, Steven Jungerwirth, Yoshiya Tanaka, Louis Bessette and Kevin Winthrop and has published in prestigious journals such as New England Journal of Medicine, Journal of the American College of Cardiology and CHEST Journal.
In The Last Decade
Nasser Khan
26 papers receiving 984 citations
Hit Papers
Peers
Nasser Khan
Mona Anand India
Pauline A. van Schouwenburg Netherlands
Claudia Baratè Italy
Norifumi Sawamukai Japan
Sheeja T. Pullarkat United States
Gerrie Stoeken‐Rijsbergen Netherlands
Vijay Joshua Sweden
Bhavisha A. Patel United States
Prajwal Boddu United States
Z Domljan Croatia
Citations per year, relative to Nasser Khan Nasser Khan (= 1×)
peers
Mona Anand
Countries citing papers authored by Nasser Khan
Since
Specialization
Citations
This map shows the geographic impact of Nasser Khan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nasser Khan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nasser Khan more than expected).
Fields of papers citing papers by Nasser Khan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Nasser Khan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nasser Khan. The network helps show where Nasser Khan may publish in the future.
Co-authorship network of co-authors of Nasser Khan
This figure shows the co-authorship network connecting the top 25 collaborators of Nasser Khan. A scholar is included among the top collaborators of Nasser Khan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nasser Khan. Nasser Khan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Charles‐Schoeman, Christina, Jon T. Giles, Nancy E. Lane, et al.. (2024). Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years. Rheumatology and Therapy. 11(1). 157–175.
2.
Brunner, Hermine I., Anna Shmagel, Gerd Horneff, et al.. (2024). Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open‐Label, Phase 1 Trial. Arthritis Care & Research. 77(5). 584–593.
3.
Burmester, Gerd R, Filip Van den Bosch, John Tesser, et al.. (2024). Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT). The Journal of Rheumatology. 51(7). 663–672.
4.
Vollenhoven, Ronald van, Vibeke Strand, Tsutomu Takeuchi, et al.. (2024). Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial. Arthritis Research & Therapy. 26(1). 143–143.
5.
Fleischmann, Roy, Ricardo Blanco, Filip Van den Bosch, et al.. (2024). Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE. Rheumatology and Therapy. 11(3). 599–615.
6.
Rubbert‐Roth, Andrea, Koji Kato, Boulos Haraoui, et al.. (2024). Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study. Rheumatology and Therapy. 11(5). 1197–1215.
7.
Fleischmann, Roy, Jerzy Świerkot, Patrick Durez, et al.. (2024). Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study. RMD Open. 10(2). e004007–e004007.
8.
Kivitz, Alan, Alvin F. Wells, Herbert S. B. Baraf, et al.. (2023). Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study. Rheumatology and Therapy. 10(4). 901–915.
9.
Charles‐Schoeman, Christina, Ernest Choy, Iain B. McInnes, et al.. (2023). MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 9(4). e003392–e003392.
10.
Silverberg, Jonathan I., Christopher G. Bunick, Peter Lio, et al.. (2023). 427 Long-term 4-year safety of upadacitinib in moderate-to-severe atopic dermatitis: results of an integrated analysis of phase 3 studies. British Journal of Dermatology. 188(Supplement_3).
11.
Winthrop, Kevin, Peter Nash, Kunihiro Yamaoka, et al.. (2022). Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. Annals of the Rheumatic Diseases. 81(2). 206–213.
12.
Yamaoka, Kunihiro, Yoshiya Tanaka, Hideto Kameda, et al.. (2021). The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Safety. 44(6). 711–722.
13.
Cohen, Stanley, Ronald van Vollenhoven, Kevin Winthrop, et al.. (2020). P209 Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the select Phase 3 clinical programme. Lara D. Veeken. 59(Supplement_2).
14.
Cohen, Stanley, Ronald van Vollenhoven, Kevin Winthrop, et al.. (2020). Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Annals of the Rheumatic Diseases. 80(3). 304–311.
15.
Winthrop, Kevin, Peter Nash, Kunihiro Yamaoka, et al.. (2020). Incidence and Risk Factors for Herpes Zoster in Rheumatoid Arthritis Patients Receiving Upadacitinib. Griffith Research Online (Griffith University, Queensland, Australia). 72. 4012–4014.
16.
Rubbert‐Roth, Andrea, Jeffrey Enejosa, Aileen L. Pangan, et al.. (2020). Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. New England Journal of Medicine. 383(16). 1511–1521.
17.
Cohen, Stanley, Ronald van Vollenhoven, Kevin Winthrop, et al.. (2019). THU0167 SAFETY PROFILE OF UPADACITINIB IN RHEUMATOID ARTHRITIS: INTEGRATED ANALYSIS FROM THE SELECT PHASE 3 CLINICAL PROGRAM. Annals of the Rheumatic Diseases. 78. 357–357.
18.
Genovese, Mark C., Michael E. Weinblatt, Jacob Aelion, et al.. (2018). ABT ‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate. Arthritis & Rheumatology. 70(11). 1710–1720.
19.
Fleischmann, Roy, Frank Wagner, Alan Kivitz, et al.. (2017). Safety, Tolerability, and Pharmacodynamics of ABT ‐122, a Tumor Necrosis Factor– and Interleukin‐17–Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis. Arthritis & Rheumatology. 69(12). 2283–2291.
20.
Wade, Michael, et al.. (2002). Is aortic valve sclerosis a manifestation of atherosclerosis?. Journal of the American College of Cardiology. 39. 421–421.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mona Anand Breakdown of academic impact, for papers by Pauline A. van Schouwenburg Breakdown of academic impact, for papers by Claudia Baratè Breakdown of academic impact, for papers by Norifumi Sawamukai Breakdown of academic impact, for papers by Sheeja T. Pullarkat Breakdown of academic impact, for papers by Gerrie Stoeken‐Rijsbergen Breakdown of academic impact, for papers by Vijay Joshua Breakdown of academic impact, for papers by Bhavisha A. Patel Breakdown of academic impact, for papers by Prajwal Boddu Breakdown of academic impact, for papers by Z Domljan